English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The role of p27 kip1  in Chronic Myeloid Leukemia (CML) has been well studied in relation to its function as a cell cycle inhibitor. However, its cytoplasmic function especially in CML remains to be seen. We studied the localization of p27 kip1  and its function during the progression of CML from chronic to blast phase. Our investigations revealed an increased localization of p27 kip1  in the cytoplasm of CD34 +  cells in the blast phase compared to chronic phase. Cytoplasmic p27 kip1  was found to modulate RhoA activity in CD34 +  stem and progenitor cells. Further, RhoA activity was shown to be dependent on cytoplasmic p27 kip1  which in turn was dependent on p210 Bcr-Abl  kinase activity. Interestingly, RhoA activity was observed to affect cell survival in the presence of imatinib through the SAPK/JNK pathway. Accordingly, inhibition of SAPK/JNK pathway using SP600125 increased apoptosis of K562 cells in presence of imatinib. Our results, for the first time, thus reveal a crucial link between cytoplasmic p27 kip1 , RhoA activity and SAPK/JNK signalling. To this effect we observed a correlation between increased cytoplasmic p27 kip1 , increased RhoA protein levels, decreased RhoA-GTP levels and increased SAPK/JNK phosphorylation in blast phase CD34 +  cells compared to chronic phase CD34 +  cells.

Increased Cytoplasmic Localization of p27kip1 and Its Modulation of RhoA Activity during Progression of Chronic Myeloid Leukemia